The curious selection process of treatments for Autism Spectrum Disorders

Matson, Johnny L.; Williams, Lindsey W.

doi:10.1016/j.rasd.2014.10.004

Cited by 17 publications

(7 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, ASD usually constitutes a significant burden for both caregivers and patients, resulting in considerable distress and reduced quality of life (Karst and Van Hecke, 2012; Khanna et al, 2011; Van Heijst and Geurts, 2015). These factors are probably dominant in leading caregivers to choose CAM treatments but beyond the goal of symptom alleviation, there are various other reasons for their use (Matson and Williams, 2015), including health promotion in general, holistic health philosophies, or the alleviation of adverse effects of conventional treatment (Levy and Hyman, 2015). The fact that the median prevalence of CAM use in this review roughly equals the prevalence of CAM use in pediatric cancer—with about two-thirds of studies reporting prevalences between 20% and 60% (Bishop et al, 2010)—underlines the perceived impact of ASD on affected families.…”

Section: Discussionmentioning

confidence: 99%

Use of complementary and alternative medicine in children and adolescents with autism spectrum disorder: A systematic review

Höfer

Hoffmann

Bachmann

2016

Autism

View full text Add to dashboard Cite

Despite limited evidence, complementary and alternative medicine treatments are popular in autism spectrum disorder. The aim of this review was to summarize the available evidence on complementary and alternative medicine use frequency in autism spectrum disorder. A systematic search of three electronic databases was performed. All research studies in English or German reporting data on the frequency of complementary and alternative medicine use in individuals with autism spectrum disorder were included. Two independent reviewers searched the literature, extracted information on study design and results, and assessed study quality using an established quality assessment tool. Twenty studies with a total of 9540 participants were included. The prevalence of any complementary and alternative medicine use ranged from 28% to 95% (median: 54%). Special diets or dietary supplements (including vitamins) were the most frequent complementary and alternative medicine treatments, ranking first in 75% of studies. There was some evidence for a higher prevalence of complementary and alternative medicine use in autism spectrum disorder compared to other psychiatric disorders and the general population. Approximately half of children and adolescents with autism spectrum disorder use complementary and alternative medicine. Doctors should be aware of this and should discuss complementary and alternative medicine use with patients and their carers, especially as the evidence is mixed and some complementary and alternative medicine treatments are potentially harmful.

show abstract

Section: Discussionmentioning

confidence: 99%

Use of complementary and alternative medicine in children and adolescents with autism spectrum disorder: A systematic review

Höfer

Hoffmann

Bachmann

2016

Autism

View full text Add to dashboard Cite

show abstract

“…Factors associated with parents' treatment selection include symptom presentation and child's age [Goin‐Kochel et al, ; Mire, Raff, Brewton, & Goin‐Kochel, ], parental education level and income [Patten, Baranek, Watson, & Schultz, ], geographic location [Murphy & Ruble, ; Mire, Hughes, Manis, & Goin‐Kochel, ], and parents' perceptions of treatment and ASD [Dardennes et al, ; Mire, Gealy, Kubiszyn, Backscheider‐Burridge, & Goin‐Kochel, ]. However, there are many unknowns about factors that influence parents' decisions to employ some treatments over others [Matson & Williams, ].…”

Section: Using Latent Class Analysis To Identify Treatment‐use Subgromentioning

confidence: 99%

Using latent class analysis to identify treatment‐use subgroups among parents of children with autism spectrum disorder

et al. 2019

View full text Add to dashboard Cite

Among parents of 2,582 children (ages 4-17 years old) with autism spectrum disorder (ASD), we used latent class analysis to identify subgroups and profiles of treatment users and included annual household income in the specification of the models, then described characteristics of each subgroup. Based on three indicators of fit (Akaike's Information Criterion, Bayesian Information Criterion, and Lo-Mendell-Rubin), six latent classes of treatment users emerged. Subgroups included users of: (a) mostly private and school speech and occupational therapies; (b) nearly all treatment types; (c) mostly speech and occupational therapies, plus intensive behavioral and "other" treatments, but little medication use; (d) private therapies almost exclusively; (e) primarily psychotropic medications; and (f) mostly school-based therapies. Income significantly predicted class differences for all but one latent class. Probabilities of families' lifetime use of nine treatment types varied depending on latent classification. Proportions of families reporting having observed children's developmental regression were largest in those with the highest overall treatment use, and these children also had the lowest cognitive and adaptivefunctioning scores and the highest ASD symptom scores. Understanding patterns of treatment use among families of children with ASD is an important first step in enhancing treatment-related selection and implementation. Autism Res 2019, 12: 843-854.Lay Summary: We identified six different groups of treatment users to help explain patterns in treatment implementation among parents of children and adolescents with autism. These included families who used: (a) mostly used private and school speech and occupational therapies; (b) nearly all treatment types (private and school therapies, intensive behavioral, biomedical, psychotropic medications, and other treatments); (c) mostly speech and occupational therapies, plus intensive behavioral and "other" treatments, but little medication use; (d) private therapies almost exclusively; (e) primarily psychotropic medications; and (f) mostly school-based therapies.

show abstract

“…People with intellectual and developmental disabilities (IDD) experience high rates of mental health and behavioural challenges, which are often treated with psychotropic medications (Lott et al 2004;Mandell et al 2008;Esbensen et al 2009;Häβler et al 2015;Spina and Leon 2017;Valenza et al 2017). Research has shown that 50-60% of people with IDD and ASD in clinical settings receive at least one psychotropic medication (Cooper et al 2009;Esbensen et al 2009), but a significant percentage of these individuals do not receive lower risk alternatives, such as counselling, occupational therapy, behavioural supports or other nondrug evidence-based interventions (Matson and Williams 2015;Lake et al 2017). Bowring et al (2017) identified a 38% prevalence of psychotropics use in a population sample.…”

Section: Introductionmentioning

confidence: 99%

“…2009; Esbensen et al . 2009), but a significant percentage of these individuals do not receive lower risk alternatives, such as counselling, occupational therapy, behavioural supports or other nondrug evidence‐based interventions (Matson and Williams 2015; Lake et al . 2017).…”

Section: Introductionmentioning

confidence: 99%

Psychotropic medications use and side effects of individuals with intellectual and developmental disabilities

Charlot

Doerfler

McLaren

2020

J intellect Disabil Res

View full text Add to dashboard Cite

Background Many people with intellectual and developmental disabilities (IDD) are treated with psychotropic medications, and polypharmacy is common. Although few studies address psychotropic side effects in the population, people with IDD have been found more likely to experience side effects than others who do not have IDD. Because many individuals with IDD may not report side effects reliably, there is risk that side effects may be missed. Methods Psychotropic use and side effects of 71 adults with IDD admitted for a 30-day crisis stay to a Systemic, Therapeutic, Assessment, Resources, and Treatment (START) Resource Center were reviewed. START is a specialised behavioural health outreach, training and crisis programme for individuals with IDD. During crisis stays, centre nurses administer the Matson Evaluation of Drug Side Effects screen, a psychometrically established psychotropic medication side effects screen developed for use with people with IDD. Data reviewed were de-identified data used to inform day-today practices and assess outcomes for individuals START served. Results The average age was 28 years, and 56% of the sample was male. All individuals were taking at least one psychotropic, while 79% were taking three or more. The average number of psychotropics used was 3.94. Antipsychotics were the most commonly prescribed medications taken by 85% of the sample; 49% of whom were not reported to have psychosis. Although the overall number of psychotropics did not correlate with Matson Evaluation of Drug Side Effects scores, the average scale scores for all participants was high in contrast to prior studies of people with IDD not taking psychotropics, with central nervous system side effects being the most commonly reported. Conclusion In the present study, data for individuals experiencing a crisis were reviewed and indicated high rates of psychotropic polypharmacy and side effects rates higher than previously reported for people with IDD not taking psychotropics. Prospective study in larger samples is needed to determine if missed or under-appreciated psychotropic side effects may play a role in behavioural health challenges of some people with IDD.

show abstract

The curious selection process of treatments for Autism Spectrum Disorders

Cited by 17 publications

References 51 publications

Use of complementary and alternative medicine in children and adolescents with autism spectrum disorder: A systematic review

Use of complementary and alternative medicine in children and adolescents with autism spectrum disorder: A systematic review

Using latent class analysis to identify treatment‐use subgroups among parents of children with autism spectrum disorder

Psychotropic medications use and side effects of individuals with intellectual and developmental disabilities

Contact Info

Product

Resources

About